These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4576115)

  • 21. [Study of the biological characteristics of strains of M. tuberculosis resistant to isoniazid and rifampin].
    Diaconescu C; Iacob L
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1984; 33(2):151-62. PubMed ID: 6093222
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis.
    Foongladda S; Roengsanthia D; Arjrattanakool W; Chuchottaworn C; Chaiprasert A; Franzblau SG
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1118-22. PubMed ID: 12546122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bacteriostatic concentration of tubazid in experimental tuberculosis].
    Butkina TK
    Probl Tuberk; 1969; 47(5):77-80. PubMed ID: 5367975
    [No Abstract]   [Full Text] [Related]  

  • 26. [The use of gene chip in detecting Mycobacterium tuberculosis resistant to rifampin and isoniazid].
    Cui ZL; Jing FX; Hu ZY; Wu ZR; Zhao JL
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jul; 27(7):439-41. PubMed ID: 15312553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance of Mycobacterium tuberculosis isolates in different populations in Greece during 1993-2002.
    Kanavaki S; Mantadakis E; Nikolaou S; Papavassiliou A; Karambela S; Anagnostou S; Falagas ME; Samonis G
    Int J Tuberc Lung Dis; 2006 May; 10(5):559-64. PubMed ID: 16704040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].
    Truffot-Pernot C; Grosset J; Bismuth R; Lecoeur H
    Rev Fr Mal Respir; 1983; 11(6):875-82. PubMed ID: 6669798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV].
    Grumbach F; Rist N
    Rev Tuberc Pneumol (Paris); 1967; 31(6):749-62. PubMed ID: 4988378
    [No Abstract]   [Full Text] [Related]  

  • 30. [The morphological reactions in the lungs during the chemotherapy of experimental tuberculosis].
    Erokhin VV
    Probl Tuberk; 2000; (5):15-9. PubMed ID: 11077845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Results of treatment of experimental tuberculosis in guinea pigs with isoniazid or with isoniazid combined with ethambutol, either in continous or in intermittent regimen].
    Sosnowski W; Rozniecki J; Tomaszkiewicz L; Bechcińska B; Cyperling I
    Gruzlica; 1970 Jan; 38(1):35-42. PubMed ID: 4984432
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of INH on coronary arteries and heart action in experimental tuberculosis].
    Dettlaff Z
    Gruzlica; 1971 Dec; 39(12):1172-9. PubMed ID: 5139236
    [No Abstract]   [Full Text] [Related]  

  • 33. Preliminary results of a controlled therapeutic trail administering INH-RMP once-weekly, after--or without--an initial period of continuous treatment.
    Eule H; Kärnbach E; Kaluza P; Herrmann H
    Scand J Respir Dis Suppl; 1973; 84():153-9. PubMed ID: 4593264
    [No Abstract]   [Full Text] [Related]  

  • 34. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.
    Mariappan TT; Singh S
    Int J Tuberc Lung Dis; 2003 Aug; 7(8):797-803. PubMed ID: 12921157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of tuberculin on the clinical course and healing processes in experimental tuberculosis].
    Krylov VA; Titov VF; Tereshin VS
    Probl Tuberk; 1994; (4):41-4. PubMed ID: 7984615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.
    Pallanza R; Arioli V; Furesz S; Bolzoni G
    Arzneimittelforschung; 1967 May; 17(5):529-34. PubMed ID: 5631580
    [No Abstract]   [Full Text] [Related]  

  • 37. Activity of rifampicin in experimental tuberculosis of the guinea pig.
    Nitti V; Catena E; Ninni A; Di Filippo A
    Chemotherapy; 1967; 12(6):369-400. PubMed ID: 4968843
    [No Abstract]   [Full Text] [Related]  

  • 38. Susceptibilities of Mycobacterium tuberculosis to isoniazid and rifampin on blood agar.
    Coban AY; Bilgin K; Uzun M; Tasdelen Fisgin N; Akgunes A; Cihan CC; Birinci A; Durupinar B
    J Clin Microbiol; 2005 Apr; 43(4):1930-1. PubMed ID: 15815022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intermittent treatment with Rifampicin in experimental tuberculosis in guinea pigs].
    Nitti V; Ninni A; Marsico SA
    Arch Tisiol Mal Appar Respir; 1969 Dec; 24(12):923-43. PubMed ID: 5312739
    [No Abstract]   [Full Text] [Related]  

  • 40. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.